MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Multi-Pathogen Vaccine Kit
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Multi-Pathogen Vaccine Kit
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • February 2020

AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee

AIVITA Biomedical to Present at 2020 BIO CEO & Investor Conference

AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Ex-Biogen CEO Michel Vounatsos
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Present at Biotech Showcase 2024

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.